Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nancy U. Lin, M.D.

Co-Author

This page shows the publications co-authored by Nancy Lin and Sara Tolaney.
Connection Strength

3.910
  1. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 Nov; 26(11):927-933.
    View in: PubMed
    Score: 0.247
  2. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun. 2021 09 21; 12(1):5563.
    View in: PubMed
    Score: 0.247
  3. Correction to: Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):305.
    View in: PubMed
    Score: 0.245
  4. Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):203-212.
    View in: PubMed
    Score: 0.240
  5. Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer. Clin Cancer Res. 2021 Mar 01; 27(5):1582.
    View in: PubMed
    Score: 0.238
  6. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Res Treat. 2021 Jun; 187(3):843-852.
    View in: PubMed
    Score: 0.237
  7. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1598-1605.
    View in: PubMed
    Score: 0.231
  8. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2020 10 15; 26(20):5310-5319.
    View in: PubMed
    Score: 0.228
  9. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Ann Oncol. 2020 09; 31(9):1231-1239.
    View in: PubMed
    Score: 0.225
  10. Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. Clin Breast Cancer. 2020 10; 20(5):395-401.e3.
    View in: PubMed
    Score: 0.224
  11. Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397.
    View in: PubMed
    Score: 0.224
  12. Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2565-2572.
    View in: PubMed
    Score: 0.221
  13. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.217
  14. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020 Jan; 179(1):113-123.
    View in: PubMed
    Score: 0.215
  15. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018; 4:10.
    View in: PubMed
    Score: 0.195
  16. Tumor subtypes and survival in male breast cancer. Breast Cancer Res Treat. 2021 Aug; 188(3):695-702.
    View in: PubMed
    Score: 0.060
  17. Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Aug; 26(8):1309.
    View in: PubMed
    Score: 0.057
  18. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 08; 26(8):1280-1284.
    View in: PubMed
    Score: 0.056
  19. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancer Discov. 2020 08; 10(8):1174-1193.
    View in: PubMed
    Score: 0.056
  20. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Ann Oncol. 2020 05; 31(5):590-598.
    View in: PubMed
    Score: 0.055
  21. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol. 2020 03; 31(3):387-394.
    View in: PubMed
    Score: 0.055
  22. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2018 02 20; 36(6):543-553.
    View in: PubMed
    Score: 0.048
  23. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017 11 06; 8(1):1324.
    View in: PubMed
    Score: 0.047
  24. Randomized trial of a physical activity intervention in women with metastatic breast cancer. Cancer. 2016 Apr 15; 122(8):1169-77.
    View in: PubMed
    Score: 0.042
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.